The major breakthrough in biotechnology is rapidly gestating and stimulating a new industrial revolution. Vigorously strengthening China’s biological genetic research and accelerating the development of the biological gene industry are of strategic significance for upgrading China’s industrial level and enhancing China’s core competitiveness. It is also an important direction for China’s future industrial development. At the China Gene Science and Industry Development Summit Forum held recently, experts, scholars, and entrepreneurs expressed their opinions on the major issues facing the development of the genetic industry, the urgent demands of enterprises, and the effects of government measures.
The genetic industry is one of the most promising industries
In recent years, China's bio-industry has been growing at a rapid rate, the scale of its industries has continued to expand, and the development of agglomeration has preliminarily shown itself. The system of independent technological innovation has been continuously strengthened, and bio-tech achievements have been industrialized on a large scale.
As one of the important industries in the bio-industry, genetic science includes genetic diagnosis reagents, gene detection, genetic engineering drugs, gene therapy, genetic transformation, etc. It is regarded as one of the most promising industries in the 21st century. The 21st century is the century of biotechnology. Biotechnology based on genetic science has been widely used in the fields of energy, chemicals, and oceans, forming a new industry and becoming a new global economic growth point.
According to reports, from 2006 to 2008, the total output value of China's biopharmaceutical industry maintained an average annual growth rate of 25%. In 2008, the total output value of China's bio-industry was close to RMB 11,000 billion, making it one of the industries with strong anti-risk capabilities during the international financial crisis.
At present, China attaches great importance to the research of life sciences and the development of the biological industry, and has arranged three special projects for the cultivation of new transgenic varieties, the creation of major new drugs, and the prevention and treatment of major communicable diseases such as AIDS and hepatitis in 16 major scientific and technological special projects, and has intensified efforts to support major organisms. Technology applications and development of important biotech products.
Academician Wang Zhizhen, vice chairman of the National Committee of the Chinese People's Political Consultative Conference and vice chairman of the Jiu San Society’s Central Committee, said at the forum that although China’s life science research still lags behind other countries in many areas, the gap between the genetic field and the world’s advanced level is not large, and some areas even lead the world. status.
Preferential policies need to adapt to the laws of industrial development
Although China's genetic industry has made great progress and its development speed is relatively faster than other industries, it still faces many challenges. While affirming the existing achievements, many scholars also expressed their views on the many issues that hampered the future development of the industry.
Wang Zhizhen believes that the lack of investment in genetic science research and development, the lack of high-quality talent required for industrial development, the promotion, popularization and promotion of gene technology, the introduction of practical supporting policies in the industry standards, access systems, and the protection of personal privacy, etc. Problems need careful study.
Yang Bangjie, vice chairman of the National People's Congress Standing Committee and Zhigong Party Central Committee, said that China’s preferential policies for high and new technology are not suitable for the development law of the biological gene industry, and the knowledge of the intellectual property patent system is relatively weak, which is bound to seriously affect the development of new drugs. .
“The problems faced by the development of the genetic industry are, for the regulated industries, the first is whether reporting can be accelerated or not. Second is whether government procurement can be implemented.†Professor of Biology and Systems Biology, Tsinghua University School of Medicine, Biology Cheng Jing, director of the Beijing National Engineering Research Center of the chip, put forward his views from the perspective of the industry.